NYSE · QGEN
QIAGEN financials
$44.40−1.36%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '25 Dec 31 | Q4 '24 Dec 31 | Q4 '23 Dec 31 | Q4 '22 Dec 31 | Q4 '21 Dec 31 | Q4 '20 Dec 31 | Q4 '19 Dec 31 | Q4 '18 Dec 31 | Q4 '17 Dec 31 | Q4 '16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — | — | — |
| Net income | — | — | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | — | — | — | — | — | — | — | — | — | — |
| EBITDA | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating cash flow | — | — | — | — | — | — | — | — | — | — |
| Free cash flow | — | — | — | — | — | — | — | — | — | — |
| Diluted shares | 218.9M | 224.7M | 230.6M | 230.1M | 225.6M | 234.2M | 226.8M | 233.5M | 233.0M | 239.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $839.0M | $663.6M | $668.1M | $730.7M | $880.5M | $598.0M |
| Short-term investments | $259.9M | $489.4M | $389.7M | $687.6M | $184.8M | $117.2M |
| Total debt | $1.65B | $1.39B | $1.51B | $1.86B | $1.94B | $1.92B |
| Total assets | $6.28B | $5.69B | $6.12B | $6.29B | $6.15B | $5.87B |
| Total liabilities | $2.50B | $2.12B | $2.31B | $2.82B | $3.05B | $3.07B |
| Shareholders' equity | $3.78B | $3.57B | $3.81B | $3.47B | $3.10B | $2.80B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology